Eikon Therapeutics, Inc. EIKN
—
7.92
(0.37)
(4.46%)
as of 25 Sep
- Market cap
- $449.0M
- P/E
- 0.0×
Follow EIKN
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
6.34 | 4.04 |
Net Debt/EBITDA |
1.07 | 0.94 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.57 | 0.55 |
Capex/Depreciation |
(1.93) | (3.34) |
Interest Coverage |
0.00 | 0.00 |
| 45.99% | 0.00% | |
| (61.45%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(76.38%) | (78.12%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(81.29) | (87.15) |
Cash per Share |
116.24 | 87.51 |
Shareholders Equity per Share |
(303.75) | (226.98) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(303.75) | (226.98) |
Free Cash Flow |
(235.26) | (219.60) |
Working Capital |
293.91 | 171.44 |
Capital Expenditures |
(46.74) | (84.80) |
Net Current Asset Value |
(1,124.85) | (835.28) |
| Other line items | ||
Quick Ratio |
6.12 | 3.91 |
Depreciation/Fixed assets |
0.17 | 0.18 |
Cash ROIC |
61.07% | 78.39% |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(65.14) | (53.50) |
Capex per Share |
(16.15) | (33.66) |
Average Payables |
9.13 | — |
Average Assets |
542.99 | — |
Average Common Equity |
(725.48) | — |
Capex to Sales |
0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates